John Paolini - Kiniksa Pharmaceuticals Chief Medical Officer
| KNSA Stock | USD 21.28 0.19 0.90% |
Executive
Dr. John F. Paolini, M.D., Ph.D., is Senior Vice President and Chief Medical Officer of the Company. He has served as our Chief Medical Officer since August 2016. From August 2015 to August 2016, Dr. Paolini was Clinical Research Head of the Cardiovascular and Metabolic Diseases Research Unit at Pfizer Inc., a pharmaceutical company, where he was responsible for bringing forward programs from preclinical through early clinical development and proof of concept. Prior to Pfizer, from August 2011 to July 2015, Dr. Paolini served as Chief Medical Officer of Cerenis Therapeutics, a biotechnology company focused on cardiovascular and metabolic diseases, where he was responsible for designing and executing clinical trials and regulatory strategy for a portfolio of products since 2019.
| Age | 59 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 23 Old Bond Street, London, United Kingdom, WIS 4PZ |
| Phone | 781 431 9100 |
| Web | https://www.kiniksa.com |
John Paolini Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Paolini against Kiniksa Pharmaceuticals stock is an integral part of due diligence when investing in Kiniksa Pharmaceuticals. John Paolini insider activity provides valuable insight into whether Kiniksa Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Kiniksa Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kiniksa Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Paolini over a month ago Disposition of 1994 shares by John Paolini of Kiniksa Pharmaceuticals at 26.74 subject to Rule 16b-3 | ||
John Paolini over six months ago Disposition of 13017 shares by John Paolini of Kiniksa Pharmaceuticals at 17.64 subject to Rule 16b-3 | ||
John Paolini over six months ago Acquisition by John Paolini of 7000 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 | ||
John Paolini over six months ago Disposition of 477 shares by John Paolini of Kiniksa Pharmaceuticals at 19.7 subject to Rule 16b-3 |
Kiniksa Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0316) % which means that it has lost $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0215) %, meaning that it created substantial loss on money invested by shareholders. Kiniksa Pharmaceuticals' management efficiency ratios could be used to measure how well Kiniksa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Kiniksa Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Capital Employed is forecasted to decline to (0.06). At present, Kiniksa Pharmaceuticals' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 262.5 M, whereas Total Assets are forecasted to decline to about 309.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Francis Burrows | Kura Oncology | N/A | |
| Michael CPA | Nuvectis Pharma | 48 | |
| Andrew Schwendenman | Replimune Group | 48 | |
| Christian JD | Gossamer Bio | 57 | |
| Charles Lin | Kronos Bio | 39 | |
| Christopher Dinsmore | Kronos Bio | 57 | |
| Yingli Ma | Structure Therapeutics American | 50 | |
| Rocio Hoyos | Kronos Bio | N/A | |
| Caryn Peterson | Gossamer Bio | 65 | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Matthew Metivier | Nuvalent | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| PharmD BCOP | Bolt Biotherapeutics | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Barbara JD | Kronos Bio | 65 | |
| Wes Trotter | Kronos Bio | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Hui Lei | Structure Therapeutics American | N/A | |
Management Performance
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0316 |
Kiniksa Pharmaceuticals Leadership Team
Elected by the shareholders, the Kiniksa Pharmaceuticals' board of directors comprises two types of representatives: Kiniksa Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kiniksa. The board's role is to monitor Kiniksa Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kiniksa Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kiniksa Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Madelyn Zeylikman, General SVP | ||
| Melissa Manno, Senior Officer | ||
| Ross Moat, Senior Officer | ||
| Rachel Frank, Senior Communications | ||
| Eben Tessari, Senior COO | ||
| Michael CPA, Chief Finance | ||
| Chad Morin, Senior Officer | ||
| John Paolini, Chief Medical Officer | ||
| Carsten Boess, Executive Affairs | ||
| FACC MD, Senior Officer | ||
| Carsten MBA, Executive Affairs | ||
| Martina Struck, Senior Affairs | ||
| Sanj Patel, CEO Chairman | ||
| Mark CFA, Senior CFO | ||
| Mei Jang, Senior Operations |
Kiniksa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kiniksa Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0316 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.32 B | ||||
| Shares Outstanding | 41.57 M | ||||
| Shares Owned By Insiders | 4.15 % | ||||
| Shares Owned By Institutions | 97.96 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (7.20) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.